Handelsbanken Fonder’s Roivant Sciences ROIV Stock Holding History

Handelsbanken Fonder’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.27M	Buy	177,209 +60,200	+51%	+$1.78M	0.02%	457
2026 Q1	$3.24M	Hold	117,009	–	–	0.01%	585
2025 Q4	$2.54M	Buy	117,009 +13,600	+13%	+$268K	0.01%	659
2025 Q3	$1.56M	Hold	103,409	–	–	0.01%	822
2025 Q2	$1.17M	Sell	103,409 -9,700	-9%	-$105K	﹤0.01%	892
2025 Q1	$1.14M	Hold	113,109	–	–	﹤0.01%	884
2024 Q4	$1.34M	Sell	113,109 -78,300	-41%	-$926K	0.01%	837
2024 Q3	$2.21M	Buy	191,409 +77,300	+68%	+$880K	0.01%	632
2024 Q2	$1.21M	Sell	114,109 -9,900	-8%	-$108K	0.01%	751
2024 Q1	$1.31M	Buy	124,009 +20,100	+19%	+$217K	0.01%	738
2023 Q4	$1.17M	Buy	103,909 +22,000	+27%	+$214K	0.01%	740
2023 Q3	$957K	Buy	81,909 +14,909	+22%	+$169K	0.01%	744
2023 Q2	$675K	Buy	67,000 +53,500	+396%	+$479K	﹤0.01%	911
2023 Q1	$100K	Hold	13,500	–	–	﹤0.01%	1526
2022 Q4	$108K	Buy	+13,500	New	+$75.1K	﹤0.01%	1509

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Handelsbanken Fonder's ROIV Position: Q2 2026 in Review

Handelsbanken Fonder increased its Roivant Sciences (ROIV) stake by 51% in Q2 2026, buying an estimated $1.78M and bringing the position to 177,209 shares worth $6.27M. The position accounts for 0.02% of the portfolio, ranked #457.

Handelsbanken Fonder first reported a position in ROIV in Q4 2022 and has held it in 15 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Handelsbanken Fonder held 177,209 shares of Roivant Sciences worth $6.27M as of Q2 2026.
Handelsbanken Fonder bought 60,200 Roivant Sciences shares in Q2 2026, an estimated $1.78M.
Roivant Sciences made up 0.02% of Handelsbanken Fonder's portfolio in Q2 2026, its #457 holding.
Handelsbanken Fonder first reported a position in Roivant Sciences in Q4 2022 and has held it in 15 quarters since.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.